jcm-logo

Journal Browser

Journal Browser

New Perspectives of Gastric Cancer: Current Treatment and Management

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: closed (31 May 2025) | Viewed by 358

Special Issue Editor


E-Mail Website
Guest Editor
Clinic of Surgery, Medicine Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
Interests: gastric cancer; neoadjuvant chemotherapy; peritoneal metastasis; HIPEC; treatment; management

Special Issue Information

Dear Colleagues,

Gastric cancer remains a significant challenge in the healthcare system. Today, complex treatment methods have become standard practice. We now have extensive data on gastric cancer treatment outcomes. However, most of these data originate from Eastern countries, making it difficult to directly apply these results to Western populations.

We conducted a retrospective analysis of medical records from patients admitted to the Department of Surgery at the Hospital of the Lithuanian University of Health Sciences, Kaunas Clinics, focusing on those diagnosed with gastric cancer. The analysis examined the impact of systemic treatments (neoadjuvant and adjuvant chemotherapy), HIPEC, and surgical techniques (open and laparoscopic) on patient survival and early and late postoperative complications.

This Special Issue invites contributions from researchers and clinicians to explore the latest findings in this critical area. We encourage the submission of original research, reviews, and clinical studies that delve into gastric cancer.

We look forward to receiving your valuable contributions to this Special Issue, which aims to shape the future of gastric cancer treatment and management.

Prof. Dr. Mindaugas Kiudelis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastric cancer
  • neoadjuvant chemotherapy
  • peritoneal metastasis
  • HIPEC
  • treatment
  • management

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

14 pages, 936 KiB  
Systematic Review
One-Stage Versus Two-Stage Gastrectomy for Perforated Gastric Cancer: Systematic Review and Meta-Analysis
by Michele Manara, Alberto Aiolfi, Quan Wang, Gianluca Bonitta, Galyna Shabat, Antonio Biondi, Matteo Calì, Davide Bona and Luigi Bonavina
J. Clin. Med. 2025, 14(13), 4603; https://doi.org/10.3390/jcm14134603 - 29 Jun 2025
Viewed by 113
Abstract
Background/Objectives: The optimal surgical management of perforated gastric cancer (PGC) in emergency settings remains controversial. Urgent upfront one-stage gastrectomy (1SG) and two-stage gastrectomy (2SG) with damage-control surgery followed by elective gastrectomy have been proposed. The aim of the present systematic review is [...] Read more.
Background/Objectives: The optimal surgical management of perforated gastric cancer (PGC) in emergency settings remains controversial. Urgent upfront one-stage gastrectomy (1SG) and two-stage gastrectomy (2SG) with damage-control surgery followed by elective gastrectomy have been proposed. The aim of the present systematic review is to compare short- and long-term outcomes between 1SG and 2SG in the treatment of PGC. Methods: A systematic review and individual patient data (IPD) meta-analysis of studies reporting data of patients undergoing 1SG vs. 2SG for PGC was conducted. The time-dependent effects of surgical interventions were assessed using a likelihood ratio test. Hazard function plots were generated via marginal prediction. Results: Ten retrospective series (579 patients) were included. Overall, 482 patients (83%) underwent 1SG, while 97 patients (17%) were treated with 2SG. A trend toward better short-term oncological outcomes and safety profiles for 2SG compared to 1SG was observed. Long-term outcomes were comparable between 1SG and 2SG, and the IPD meta-analysis showed no statistically significant difference between the two approaches in terms of OS or hazard for mortality at all time points. A trend towards a higher hazard for mortality was observed for 1SG in the first 20 months postoperatively. Conclusions: Our analysis suggests that 1SG and 2SG yield comparable short-term outcomes, although 2SG may be associated with a lower medium-term mortality risk. Further research is needed to identify key factors to improve clinical judgments and decision-making in PGC. Full article
(This article belongs to the Special Issue New Perspectives of Gastric Cancer: Current Treatment and Management)
Show Figures

Figure 1

Back to TopTop